Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720

• Published in: Journal of clinical oncology Vol. 26; no. 30; pp. 4934 - 4939
• Main Authors: BAER, Maria R, GEORGE, Stephen L, ANASTASI, John, BLOOMFIELD, Clara D, LARSON, Richard A, CALIGIURI, Michael A, SANFORD, Ben L, BOTHUN, Sandra M, MROZEK, Krzysztof, KOLITZ, Jonathan E, POWELL, Bayard L, MOORE, Joseph O, STONE, Richard M
• Format: Journal Article
• Language: English
• Published: Baltimore, MD American Society of Clinical Oncology 20.10.2008; Lippincott Williams & Wilkins
• Subjects: Aged; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Hematologic and hematopoietic diseases; Humans; Immunotherapy; Interleukin-2 - therapeutic use; Leukemia and Bone Marrow Transplantation; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - mortality; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical sciences; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome; Tumors; Human; Acute myelogenous leukemia; Prognosis; Low dose; Cytokine; B cell neoplasm; Malignant hemopathy; B-Lymphocyte; First complete remission; Cancerology; Treatment; Interleukin 2; Immunotherapy; Elderly; Age; Cancer
• ISSN: 0732-183X; 1527-7755
• DOI: 10.1200/JCO.2008.17.0472

Cancer and Leukemia Group B (CALGB) 9720 evaluated subcutaneous low-dose recombinant interleukin-2 (rIL-2) maintenance immunotherapy as a strategy for prolonging remission in older patients with acute myeloid leukemia (AML). AML patients age 60 years and older in first complete remission after induction and consolidation chemotherapy were randomly assigned to no further therapy or a 90-day regimen of 14-day cycles of low-dose rIL-2, aimed at expanding natural killer (NK) cells, followed by 3-day higher doses aimed at activating cytotoxicity of expanded NK cells to lyse residual AML cells. All randomly assigned patients were included in an intention-to-treat analysis. A total of 163 (64%) of 254 patients who completed induction and consolidation chemotherapy on CALGB 9720 were randomly assigned to rIL-2 (n = 81) or no further therapy (n = 82); the most common reasons for lack of random assignment were patient refusal and relapse. Fifteen patients randomly assigned to rIL-2 never initiated it because of refusal, intercurrent medical problems, or relapse, and 24 patients initiated rIL-2 but stopped early because of toxicity or relapse. Grade 4 toxicities during rIL-2 therapy included thrombocytopenia (65%) and neutropenia (64%), and grade 3 toxicities included anemia (33%), infection (24%) and malaise/fatigue (14%). Forty-two patients (52%) randomly assigned to rIL-2 completed the full 90-day course. Patients in both arms had similar distributions of both disease-free (combined median = 6.1 months; P = .47) and overall survival (combined median = 14.7 months; P = .61) after random assignment. Moreover, the 42 patients who completed all planned therapy did not show prolongation of disease-free or overall survival. Low-dose rIL-2 maintenance immunotherapy is not a successful strategy in older AML patients.